With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

We recently published 10 Stocks Jim Cramer Talked About . Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...

All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their ...

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...

More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...

The regulator’s Office of Prescription Drug Promotion (OPDP) has already sent out two letters alleging “false or misleading” ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...